Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Rating) shares traded up 15.7% on Thursday . The stock traded as high as $0.48 and last traded at $0.45. 9,936 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 507,309 shares. The stock had previously closed at $0.39.
Bluejay Diagnostics Price Performance
The stock has a market capitalization of $9.07 million and a PE ratio of -1.02. The business's fifty day moving average price is $0.68 and its 200-day moving average price is $0.92.
Get Bluejay Diagnostics alerts:Bluejay Diagnostics (NASDAQ:BJDX – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, analysts expect that Bluejay Diagnostics, Inc. will post -0.29 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC purchased a new stake in shares of Bluejay Diagnostics during the second quarter valued at approximately $54,000. Virtu Financial LLC purchased a new position in Bluejay Diagnostics during the second quarter valued at $45,000. Finally, Millennium Management LLC purchased a new position in Bluejay Diagnostics during the second quarter valued at $27,000. 0.94% of the stock is currently owned by institutional investors.Bluejay Diagnostics Company Profile
(Get Rating)
Bluejay Diagnostics, Inc, a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components.
Recommended Stories
- Get a free copy of the StockNews.com research report on Bluejay Diagnostics (BJDX)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.